^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | IK-930 (TEAD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy
Published date:
10/12/2022
Excerpt:
Consistently, combination of IK-930 with MEKi and EGFRi resulted in apoptosis in vitro and led to strong antitumor activity in vivo in KRAS and EGFR mutant xenografts models of CRC and NSCLC.
Secondary therapy:
EGFR inhibitor; MEK inhibitor
